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Abstract 
Arsenic compounds such as sodium arsenite (SA) and arsenic trioxide (ATO) are toxic to human. Primarily, we 
pursued to outline the cell death modes caused by arsenic compounds and to address what proteins would be 
responsible for arsenite-induced cytotoxicity. Both SA and ATO substantially exhibited cytotoxic activity in 
L929 cells. Necrostatin-1 (Nec-1) treatment significantly protected cell death mediated by arsenic compounds, 
suggesting that cells are committed to die in a programmed necrotic way. A geldanamycin analog DMAG 
destabilized receptor interacting protein 3 (RIP3) and concomitantly protected cells from SA toxicity. Using 
interfering RNAs, we eventually found that RIP3 was responsible for its antagonizing effects on SA. Therefore, 
it is proposed that arsenic compounds execute necroptotic cell death of L929 via a RIP3 dependent pathway.  
Keywords: Arsenite; Heat shock protein 90; Programmed necrosis; Receptor interacting protein 3. 
1. Introduction 
 Arsenic compounds are one of the most environmentally hazardous substances so that they are classified as 
human carcinogens [1, 2]. In chemistry, arsenic compounds have various oxidation states. Both pentavalent 
[arsenate, AS
5+
] and trivalent [arsenite, AS
3+
] species are most prevalent in the nature and exhibit toxicological 
effects on human [2].  
------------------------------------------------------------------------ 
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Particularly, arsenite acts as a double-edged sword, that is, it is associated with various cancers, including 
tumors of the lung, skin, bladder, and liver [3-5] while arsenic trioxide (ATO) has been widely used in the 
treatment of relapsed acute promyelocytic leukemia (APL) and human immunodeficiency virus (HIV) type 1 [6-
8]. As can be inferred from harnessing of arsenite as an anticancer drug, arsenite has been reported to cause cell 
death in a caspase-dependent manner [9-12]. With caspase activation, generation of oxidative stress was 
suggested to be essential for arsenite-mediated cytotoxicity. On the contrary, there have been the report that 
arsenic trioxide (ATO) is effectively used in treatment of malignancies via a caspase-independent pathway. 
Specifically, ATO induces autophagy in T-lymphocytic leukemia and myelodysplastic syndrome, and notably in 
malignant gliomas, which show resistance to various commonly used therapies [13-16]. Also, it is involved in 
triggering a caspase-independent necrotic cell death via the mitochondrial pathway [17, 18].  When it comes to 
cell death, necrosis and apoptosis are exclusively distinctive in the aspects of morphology and its underlying 
molecular events [19, 20]. Meanwhile, a specialized necrosis coined “programmed necrosis or necroptosis” has 
been generally regarded as an alternative cell death mode activated under the specific condition when tumor 
necrosis factor alpha (TNFα)-mediated apoptotic machinery is defective [21]. Besides TNFα, it has been 
possibly suggested that a few chemicals and heavy metals can induce necroptosis-like cell death, distinct from 
apoptosis [22]. Similar to TNFα-mediated necroptosis, chemicals- or heavy metal-induced cell death is reversed 
by necrostatin-1 (Nec-1), a specific inhibitor receptor interacting protein 1 (RIP1) [23-25] . Once TNFα receptor 
(TNFR) ligated, RIP1 functions as a scaffolding protein of TNFα signaling, and transmits death signals to 
downstream effectors by forming complex with RIP3. Therefore, RIP1 and RIP3 are proposed to be crucial 
proteins that can determine cell death in favor of necroptosis when cells are subjected to stresses [26-28]. Here, 
we hypothesized that a chemical but not TNFα could also induce necroptosis through RIP1 or RIP3. 
Furthermore, we sought to delineate the underlying mechanisms by which arsenite could induce cell death via 
non-apoptotic pathway. To this end, some chemicals were preliminary tested if those chemicals would mediate 
necroptosis-like cell death. In particular, sodium arsenite (SA) could effectively promote cell death in L929, a 
specialized cell line for necroptosis. L929 cells used in this research have been known as a model system of 
necroptosis that can be induced upon TNFα stimulation since they are defective in caspase activation. The cell 
proliferation assay (MTS) and flow cytometric (FACS) data demonstrated that both sodium arsenite and ATO 
were cytotoxic at a 20 M concentration, ATO being slightly more potent than SA. SA-mediated killing effects 
were significantly reversed by Nec-1 but not zVAD, a pan-caspase inhibitor. Furthermore, RNA interference 
study revealed that RIP3 but not RIP1 was responsible for SA-mediated necroptotic cell death. Taken together, 
we suggest that SA induces necroptosis-like cell death via a RIP3-dependent route. This study will provide 
mechanistic basis for understanding SA-triggered signaling pathways leading to cell death, and support its 
clinical feasibility to fight against drug-resistant cancers that can evade apoptosis surveillance. 
2. Materials and Methods 
2.1. Reagents  
Sodium arsenite (SA) and arsenic trioxide (ATO) were obtained from Wako (Richmond, VA, USA). zVAD-fmk 
(zVAD), necrostatin-1 (Nec-1), N-acetylcystein (NAC), butylated hydroxyanisole (BHA), propidium iodide (PI) 
and 2′, 7′-dichlorodihydrofluorescein diacetate (DCFDA) were available from Sigma-Aldrich (St. Louis, MO, 
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USA). The 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (DMAG), a geldanamycin (GA) 
derivative, was kindly given from Ulsan National Institute of Science and Technology (UNIST, Ulsan, South 
Korea). Anti-RIP1 and anti-RIP3 were from BD Pharmingen (San Diego, CA, USA) and ProSci (Poway, CA, 
USA), respectively. Cell proliferation assay kit (MTS reagent, a tetrazolium salt) was bought from Promega 
(Madison, WI, USA). HiperFect as a transfection reagent of siRNAs was purchased from Qiagen (Valencia, CA, 
USA). FITC-annexin V (AnxV) detection kit was bought from BD Biosciences (Franklin Lakes, NJ, USA). 
Other chemical reagents used were of analytical grade.  
2.2. Cell line and cell culture 
L929, a mouse fibrosarcoma cell line (ATCC CCL-1) was obtained from American Type Culture Collection 
(ATCC) (Manassas, VA, USA). Cells were grown in high-glucose Dulbecco’s modified Eagle’s (DME) 
medium supplemented with 1% penicillin/streptomycin and 10% fetal bovine serum (FBS), and allowed to 
incubate at 37°C in a 5% CO2 incubator. 
2.3. Dose responses of cells to arsenic compounds and effects of Nec-1 on arsenic chemicals-induced 
cytotoxicity 
L929 cells were cultured in a 96-well plate at a density of 1 x 10
4 
cells/well. Cells were exposed to increasing 
doses of SA and ATO (10-50 M). Furthermore, cells were treated with SA (20 M) and ATO (10 M) at a 
fixed concentration in the presence or absence of 10 M Nec-1 for 24 h. To measure the cell viability, MTS 
assay was performed according to the manufacturer’s protocol.  
2.4. Effects of DMAG on SA-mediated cell toxicity 
Primarily, cellular levels of two necroptosis regulators RIP1 and RIP3 after DMAG pretreatment were examined 
by immunoblot. Cells were pretreated with DMAG (1 and 5 M) for 15h and then were lysed in M-PER reagent 
(PIERCE, Rockford, IL) for 20 min on ice. The resulting lysates were spun in a microcentrifuge for 20 min at 
4°C, and then the supernatants were taken. Aliquots of the cell lysates (20 g) were run on 10% SDS–
polyacrylamide gels (SDS-PAGE), and Western blotting was performed with antibodies against RIP1, RIP3 and 
β-actin. The interest proteins were visualized by enhanced chemiluminescence (ECL) in accordance with the 
manufacturer’s instructions. To examine the effects of DMAG pretreatment on SA- or ATO-caused cytotoxicity, 
cells were pretreated with 1 M DMAG 15 h and then exposed to SA or ATO at 20 M and 10 M, 
respectively. Furthermore, to verify the role of Nec-1 on arsenic compounds after DMAG treatment, DMAG-
pretreated cells were left treated with SA or ATO together with 10 M Nec-1. Following 24 h incubation, cell 
viability was determined by MTS.  
2.5. RIP1- or RIP3-specific siRNA design, synthesis and transfection 
Interference RNAs targeting RIP1 or RIP3 were specifically designed as described below. In brief, siRNA 
sequences were deduced from uploading cDNA sequences into the query form of the Integrated DNA 
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Technologies (IDT) Web server. The resulting siRNAs were synthesized by Bioneer (Daejeon, South Korea). 
After repetitive testing of siRNAs prepared, a specific siRNA that can downregulate RIP1 or RIP3 expression 
was finally chosen for subsequent experiments. The siRNA sequences for RIP1 and RIP3 were listed in the 
previous article [26]. For reference, TNFα-related apoptosis-inducing ligand receptor 4 (TR4) siRNA was used 
unless otherwise stated. Transfection of siRNAs into cells was carried out as previously described [26]. Briefly, 
either RIP1 or RIP3 siRNA (100 nM) selected was transfected into 0.25 ml culture media of L929 cells using 
HiperFect (6 l) as a transfection agent according to the instruction manual provided by the supplier. On the 
next day, the cells were exposed to arsenite or arsenite plus Nec-1. Cytotoxicity was determined by MTS assay 
24 h after exposure to arsenic compounds, and expressed as % viability of treated group relative to the untreated 
control. 
2.6. Flow cytometric analyses 
L929 cells were plated at 2 x 10
5
 cells/each well of the tissue culture plates. For FACS analyses (FACSVerse 
instrument, BD Bioscience, CA), cells were treated with various combinations of test compounds under 
examination for 24 h, and then stained with AnxV and PI. For statistical significance, at least 10,000 cellular 
events were acquired per sample to get the % cell death quantified.  
2.7. Intracellular ROS detection 
Cells were treated with 5 M cell-permeant 2′, 7′-dichlorodihydrofluorescein diacetate (DCF-DA) fluorescent 
probe for 1 h, and then dissociated with trypsin. Flow cytometer is employed to detect intracellular ROS 
production in collected cells. A total of 10,000 events were recorded for the fluorescence of DCFDA on FL-1 
channel (520 nm). 
2.8. Statistics 
The results obtained were expressed as mean ± standard deviation from at least three independent experiments. 
The significance was set at p < 0.05 for each analysis using student’s t-test. 
3. Results 
3.1. Dose responses of L929 to arsenic compounds for their cytotoxicity, and protection from arsenite-
mediated cytotoxicity by Nec-1 
Of most common trivalent arsenic compounds, SA and ATO were tested in L929 cells to plot dose-response 
curves for cytotoxicity. As indicated in MTS assay of Fig. 1A, SA was toxic over 10~20 M concentrations 
whereas ATO killed cells more drastically even at a lower concentration of 10 M, and thereafter, both SA and 
ATO kept cells viable at a 50% level. As an effort to roughly outline SA-mediated cell death, a RIP1 inhibitor 
Nec-1, which regulates programmed necrosis, was employed (Fig. 1B).  
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Figure 1: Dose responses of L929 to arsenic compounds, and protective effects of Nec-1 against arsenic 
compounds. (A) To plot dose-response curves of cells to sodium arsenite (SA) and arsenite trioxide (ATO), cells 
were exposed to various concentrations of arsenic chemicals, ranging from 10 to 50 M for 24 h. (B) Also, a 
RIP1 specific inhibitor Nec-1 was employed to delineate cell death mode caused by arsenite. Cells were treated 
with either SA (20 M) or AT (10 M) in the presence or absence of Nec-1. Cell toxicity was measured by 
MTS assay according to the manufacturer’s protocol and expressed as % viability relative to control group. (C) 
Flow cytometric analyses of cells exposed to arsenite alone or arsenite plus Nec-1. Cells grown in a 12 well-
plate were treated with SA or ATO (10 and 20 M) in the absence or presence of 10 M Nec-1 for 24 h, and 
then stained with AnxV and PI. Each cell in the live or dead cell populations was analyzed by FACS. 
Statistically significance: ***p<0.005 against group in the absence of Nec-1. 
Cells treated with either 20 M SA or 10 M ATO was significantly protected in the presence of Nec-1, 
although cells exposed to ATO was less rescued than those subjected to SA exposure by a necroptosis inhibitor. 
To further examine cell death profiles caused by SA, FACS analyses were carried out after cells were stained 
with PI and AnxV-FITC (Fig. 1C). In line with MTS results, SA at a lower concentration (10 M) did not cause 
cell death substantially. However, nearly 50% of total cells were dead when treated with 20 M SA, revealing 
that one half of dead cell population was double positive for PI and AnxV and the other half was single positive 
for PI. When compared with SA, ATO caused considerably cell death at 10 M concentration, but did not seem 
to exhibit a linear dose response over 10~20 M as anticipated in MTS results. Moreover, Nec-1 treatment 
effectively reduced the dead cell populations consisting of PI-single positive and PI/AnxV-double positive cells 
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which were induced by SA. Unlike SA, though, development of cell death caused by 20 M ATO was not 
reversed by Nec-1 treatment.  
3.2. The protective effects of DMAG on SA-caused cytotoxicity in L929 cells 
Cytotoxic responses of L929 cells to SA were further monitored following treatment of DMAG, an Hsp90 
inhibitor. Primarily, expression levels of key necroptosis regulators RIP1 and RIP3 were investigated when 
Hsp90 was functionally inhibited by DMAG. Immunoblot analysis revealed that DMAG treatment noticeably 
led to degradation of RIP1 and RIP3 in a dose dependent manner (Fig. 2A). 
 
Figure 2: The effects of DMAG on SA-mediated cytotoxicity in L929 cells. (A) RIP1 and RIP3 expression in 
L929 cells which were treated with DMAG. Cells were treated with 1 and 5 M DMAG for 15 h, and then 
harvested cells were lysed to run the resulting lysates onto SDS-PAGE. Transferred membranes were 
immunoblotted with antibody against RIP1 or RIP3. (B) Cytotoxic responses of DMAG-pretreated cells to SA. 
L929 cells were pretreated with 1 M DMAG and then exposed to 20 M SA for 24 h. Nec-1 (10 M) was also 
tested to monitor whether it could still be effective in protecting SA-mediated cell death following DMAG 
pretreatment. Cell viability was evaluated by MTS assay. (C) Flow cytometric analyses of L929, which were 
pretreated with DMAG or vehicle, subjected to SA exposure. L929 cells plated into a 12 well plate were 
pretreated with DMAG for 15 h and then were exposed to 20 M SA for 24 h. The harvested cells were stained 
with AnxV and PI and then cell survival/death profiles were determined by flow cytometry. Shown are the 
representative flow cytometric dot plots of three independent data. ***p<0.005 versus vehicle group. 
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RIP1 proteins disappeared more rapidly than RIP3 upon DMAG exposure. Moreover, MTS and FACS data 
showed that DMAG pretreatment protected effectively cells from SA-mediated cell death (Fig. 2B and 2C). 
Protective effects of DMAG against SA-induced cytotoxicity were more manifested than those of Nec-1. MTS 
data revealed that cells pretreated with DMAG were refractory to SA exposure. Furthermore, flow cytometry 
reinforced that most PI-positive populations in SA-treated group were significantly reduced by DMAG, 
indicating that protective effects of DMAG are fairly superior or equivalent to Nec-1. As expected in MTS 
results, Nec-1 itself exhibited the same antagonizing effects on cells exposed to SA. Cells treated with DMAG 
and Nec-1 was protected from SA toxicity in a similar level to those with DMAG alone.  
3.3. Role of RIP1 or RIP3 on SA-executed cell death      
 
Figure 3: The differential effects of RIP1 or RIP3 knockdown on SA-mediated cell death. (A) Expression levels 
of RIP1 and RIP3 following a RNA interference targeting RIP1 or RIP3. Silencing protocols were carried out as 
described in Materials and Methods. To check the outcomes of RNA interferences, L929 cell lysates were 
prepared and subjected to SDS-PAGE for immunoblotting with antibodies against RIP1 or RIP3. (B) Effects of 
RIP1 or RIP3 knock-down on SA-mediated cytotoxic activity. Following siRNA transfection, the cells were 
subjected to stimuli such as arsenite or arsenite plus Nec-1. Cytotoxicity in L929 cells was determined by MTS 
assay 24 h after exposure to arsenic compounds, and expressed as % viability of treated group relative to the 
untreated control. (C) Flow cytometric analyses of L929, which were knocked-down with RIP1 or RIP3 
siRNAs, subjected to SA exposure. RIP1 or RIP3 knocked-down L929 cells were stimulated with 20 M SA for 
24 h. The subsequent cells were stained with AnxV and PI, quadrant profiles of which were determined by flow 
cytometry. Shown are representative data out of at least three independent measurements. ***p<0.005 against 
mock group. 
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To address which death-specific molecules could be involved in arsenic compounds-mediated cytotoxicity, 
expression levels of RIP1 or RIP3 were reduced by using RNA interferences (Fig. 3). Western blot 
demonstrated that down-regulation of either RIP1 or RIP3 was well verified in cells transfected with siRNA 
specific to it (Fig. 3A). In this experiment, transient down-regulation of RIP1 or RIP3 itself did not affect cell 
viability considerably (data not shown). Responses of cells to SA were investigated following the knock-down 
of either RIP1 or RIP3 gene (Fig. 3B). As shown in MTS data, interference of RIP3, but not of RIP1 protected 
significantly cells from SA-mediated toxicity. Interestingly, Nec-1 failed to relieve the toxicity of SA in RIP1 
knocked-down cells. For more details, FACS analyses were carried out with cells subjected to the same 
conditions as above (Fig. 3C). It was of note that RIP1 silencing rendered cells sensitive to SA as compared with 
mock control group. Roughly, PI-positive cells in RIP1-silenced group were increased as double as those in 
mock group. By contrast, RIP3 silencing protected cells from SA toxicity. Unlike RIP1 knocked-down cells, 
intriguingly, application of Nec-1 to cells transfected with mock or siRIP3 effectively rescued cells from SA-
mediated toxicity.  
3.4. Intracellular ROS production and antioxidants’ effects in SA-treated L929 cells 
Cell death modalities and intracellular ROS in SA-treated L929 cells were determined by flow cytometer (Fig. 
4A and 4B). The flow cytometric analyses demonstrated that SA-mediated cell death was significantly rescued 
by both ROS scavengers, NAC and BHA (Fig. 4A). Specifically, SA treatment caused cells to be in the upper 
right quadrant being double-positive for AnxV and PI. AnxV
+
/PI
+
 double positive events (40 %) in cells 
exposed to SA were reduced to as low as 2~3 % by either NAC or BHA. Consistent with AnxV/PI data, ROS-
positive live population was considerably increased when L929 cells were subjected to SA exposure (Fig. 4B). 
After treatment of cells with either SA alone or SA in combination with ROS scavengers, changes in ROS 
production were analyzed in flow cytometry (Fig. 4B). ROS production in cells treated with SA was remarkable, 
as indicated by an increase (30 %) in events of P1 region relative to non-stimulated group (NS). Not only NAC 
but also BHA obviously reversed SA-induced ROS generation although the scavenging effect of NAC appeared 
to be more effective than that of BHA.   
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Figure 4: The involvement of ROS in SA-induced cytotoxicity. L929 cells were preincubated with 5 mM NAC 
or 0.1 mM BHA for 1 h, and then exposed to 20 M SA for 24 h. Each treated group was stained with AnxV 
and PI for analyzing cell death modality (A). Another set of experiments was undertaken for the same treated 
group as above, and then cells was stained with 5 M DCFDA for 1hr and then subjected to flow cytometric 
analyses for intracellular ROS detection (B). The same numbers of events, gated from SSC/FSC plot of treated 
group, were represented in histogram for DCF fluorescence intensity. Percentage of a population within P1 
region showing events with high fluorescence intensities was determined to compare ROS levels generated 
between treated groups. All data are representative of three independent flow cytometric analyses. 
4. Discussion 
Arsenite plays pleiotropic effects on a variety of biological events, including inflammation, cell survival and 
death. Specifically, arsenite is proposed to invoke vascular inflammation and further to develop pathology of 
vascular disease by enhancing the TNFα-induced VCAM-1 expression via regulation of AP-1 and NF-κB 
activities [29]. In addition, it has recently been revealed that embryonic stem cells exposed to SA do not make 
self-renewal and undergo apoptotic death via suppression of AKT and Stat3 activation [30]. In this article, it has 
been demonstrate that cell cycle is arrested on G2/M and apoptosis is later executed by the mitochondrial 
pathway. Furthermore, ATO has been reported to have differential effects on death modes of cells derived from 
various tissues [31-33]. Specifically, HeLa, calf pulmonary artery endothelial cells (CPAEC) and human 
umbilical vein endothelial cells (HUVEC) undergo apoptotic cell death when treated with ATO. However, there 
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have been still contradictory reports that arsenic compounds cause cell death in a caspase-independent manner. 
ATO triggers caspase-independent necrotic cell death via Bcl-XL-sensitive mitochondrial pathway [17]. 
Moreover, blockade of glutathione synthase by buthionine sulfoximine (BSO) augments ATO-mediated 
necrosis, reasoning that ROS are substantially involved in necrosis-like cell death.  Initially, an alternative cell 
death mode called programmed necrosis or necroptosis has been introduced to describe the backup cell death 
unmasked when the default cell death (apoptosis) is defective upon TNFα stimulation. Besides an inflammatory 
cytokine TNFα, however, a number of chemicals or heavy metals have been reported to provoke necroptosis-
like cell death. Shikonin and alkylating agent cause cell death with non-apoptotic features by various criteria 
[34, 35]. Notably, severe DNA damage by alkylating agent is suggested to activate PARP-1 that overuses NAD
+
 
as a substrate, eventually causing energy crisis and necrosis [36]. Whatever it may be TNFα or other necrotic 
death inducers, application of Nec-1 effectively block cells from undergoing necroptotic cell death. 
Accordingly, it is tempting to speculate that chemicals or heavy metals, like TNFα-induced necroptosis, may 
also require a series of its associated proteins for mediating necroptotic cell death.  Meanwhile, DMAG is an 
inhibitor of Hsp90, which is required for stability and activity of a variety of client proteins. Among the 
interacting proteins of Hsp90, RIP1 has been already known as a client protein, and RIP3 has recently been 
suggested to be a putative client candidate of it [22, 37]. In fact, the functional disruption of Hsp90 results in 
degradation of death domain kinase RIP, and subsequent suppression of TNFα-induced NFκB activation, 
proposing that RIP1 is necessary for TNFα/NFκB signal transduction [37, 38]. As a result, RIP1 depletion 
sensitizes cells to TNFα by switching from necrosis to apoptosis, indicating that RIP1 can function as an 
apoptosis suppressor in L929 cells [39]. Under the condition that RIP1 and RIP3 were destabilized by an Hsp90 
inhibitor, in our result, SA-mediated cytotoxic activities were considerably ameliorated compared with vehicle 
group, reckoning that either RIP1 or RIP3 contributes to reduction of cellular damage caused by SA. However, 
it could not be ruled out that other client proteins than RIPs might be responsible for the protective effects of 
DMAG. To address what necroptosis-regulating proteins are involved in the refractory response of DMAG-
treated cells to SA exposure, RNA interferences targeting RIP1 or RIP3 were primarily employed. Intriguingly, 
RIP3 knockdown effectively protected cells from SA-induced cytotoxicity whereas RIP1 silencing rendered 
cells more sensitive to SA. It can be suggested that RIP3 but not RIP1 is prerequisite for SA-mediated cell 
death. We have already demonstrated that either TNFα or zVAD causes cell death in a RIP3- or RIP1-dependent 
pathway, respectively. Therefore, it might be plausible that SA could transmit directly its death signal to RIP3 
via an unidentified route. Otherwise, SA could provoke TNFα secretion from L929 cells, which are 
subsequently liable to undergo necroptotic cell death via death receptor. Moreover, exposure of RIP1 knocked-
down L929 cells to SA was not rescued by Nec-1 treatment, suggesting that adequate expression of RIP1 is 
essential for protective efficacy of Nec-1 against necroptosis. Nec-1 has been initially developed as a 
necroptosis inhibitor targeting specifically RIP1. However, it has been proposed that Nec-1 can have off-target 
effects or may target other molecules than RIP1. According to our latest results, Nec-1 protects cells from either 
TNFα or zVAD, which is proposed to transmit death signal through a RIP3- or a RIP1-dependent route, 
respectively [22]. Moreover, Nec-1 has been reported to exerts RIP1-dependent and –independent effects in the 
process of necroptosis and T cell activation [40]. Although there remain controversies regarding authentic 
molecular target of Nec-1, it is still evident that protective effects of Nec-1 depends on RIP1 expression.  
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Figure 5: A proposed schematic model for SA-mediated cell death in L929 cells. Both RIP1 and RIP3, two 
well-known key regulators of TNFα-mediated necroptosis, are also required for SA-induced cytotoxicity. RIP3 
in combination with RIP1 can execute SA-mediated necroptosis, which can be reversed by a RIP1-specific 
inhibitor Nec-1. RIP1 knockdown via RNA interference enhances cytotoxic response to SA considerably, 
promoting necroptotic cell death. However, even Nec-1 treatment did not protect L929 with low levels of RIP1 
from SA toxicity. Symbols – and + indicate protection and promotion of necroptosis, respectively, and a symbol 
X represents that Nec-1 is not effective on SA-induced necroptotic cell damage at the low levels of RIP1. 
Among several possible mechanisms for SA cytotoxicity, ROS have been suggested to be one of decisive 
mediators to execute cell death. Low doses of arsenite induce ROS production and ROS-associated 
mitochondrial membrane depolarization [41, 42]. During SA-mediated tumor promotion, hydrogen peroxide is a 
key player of signaling pathway for activation of p70
s6k
 and extracellular signal-regulated kinase [43, 44]. As 
with being consistent with SA-caused time-dependent viability loss (MTS data), in our results, SA induced ROS 
production in a time dependent manner. Both a potent antioxidant NAC and a lipophilic ROS scavenger BHA 
blocked ROS generation from SA-treated cells, protecting cells from SA-mediated damage. This result was 
different from previous data showing the contradictory effects of two ROS scavengers against TNFα-induced 
ROS [21, 22]. It has been reported that BHA but not NAC neutralizes TNFα-generated ROS production with 
effective protection of TNFα-induced necroptosis. It suggests that intracellular sources and reactive 
intermediates of ROS produced by TNFα can be different from those produced by SA. Although both TNFα and 
SA require RIP3 to promote caspase-independent cell death, intracellular reactive intermediates including ROS 
can be differently induced in a death content-specific manner. As summarized in Fig. 5, SA induces necroptosis-
like cell death in a RIP3 dependent manner. Expression levels of another key necroptotic protein RIP1 affect 
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SA-induced cell death significantly. In fact, knockdown of RIP1 by RNA interference makes L929 cells more 
sensitive to TNFα than normal levels of RIP1 do. Also, a RIP1 specific inhibitor Nec-1 effectively reverses SA-
mediated toxicity in the presence of RIP1 while it does not in RIP1 knocked-down cells. This study suggests 
that expression of RIP1 can regulate positively or negatively SA-mediated necroptosis. For instances, basal 
levels of RIP1 can to some extent suppress RIP3-mediated necroptosis, but depletion of cellular RIP1 by 
silencing can render cells more sensitive to SA.   
5. Conclusion 
In conclusion, we propose that SA mediates necroptotic cell death of L929 cells via a RIP3-dependent pathway. 
Extensive efforts will be further carried out to disclose its underlying mechanisms and identification of proteins 
relevant to arsenite-mediated cell death. These consequences will provide perspectives on the feasibility of SA’s 
clinical use or on chemo-preventive strategy against SA. 
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